Navi Mumbai: Navi Mumbai Municipal Corporation (NMMC) on Thursday inaugurated an advanced microbiology laboratory at the ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...
Files Quarterly Report Highlighting Broad-Spectrum Antiviral Candidate NV-387. NanoViricides, Inc. (NYSE American: NNVC) filed its Form 10-Q for the quarter ended Sept. 30, 2025, and detailed progress ...
1d
NanoViricides, Inc. Has Filed its Quarterly Report – Subsequent Raise Has Fortified Fiscal Position
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...
The person was infected with a strain that has previously been reported in animals but never before in humans. ..
With the onset of winter and rising flu rates in the kingdom, warnings increase about the spread of seasonal respiratory ...
How can we monitor the cross-species transmission of avian flu? The answer is FluWarning, a digital system that reports ...
Merck said on Monday it expects a commercial opportunity exceeding $5 billion from Cidara Therapeutics' experimental flu drug ...
A mutated strain of influenza A, H3N2 subclade K, is surging worldwide, sparking concerns about a severe flu season in the ...
Outcomes validate the company’s PTAP platform as a foundation for a rapid, adaptable antiviral modality across animal and ...
The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...
The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback